---
title: "Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 | CAI Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292908660.md"
description: "Caris Life Sciences (NASDAQ: CAI) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. The company will host a live webcast at 3:30 p.m. CT to discuss these results. A replay of the webcast will be available shortly after the call on the Investor Relations section of the Caris Life Sciences website."
datetime: "2026-07-16T04:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292908660.md)
  - [en](https://longbridge.com/en/news/292908660.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292908660.md)
generator: "portal-rs"
---

# Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 | CAI Stock News

, /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026.

Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.

Webcast Details:

Date: Wednesday, August 5, 2026  
Time: 3:30 p.m. CT (4:30 p.m. ET)  
Live Webcast: https://edge.media-server.com/mmc/p/ff8xb4qs

A replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.

About Caris Life Sciences  
Caris Life Sciences® (Caris) is a leading TechBio company actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. 

Caris Life Sciences Media:  
Corporate Communications  
CorpComm@CarisLS.com  
214.294.5606

Investor Relations:  
IR@CarisLS.com  
917.689.3511

SOURCE Caris Life Sciences

### Related Stocks

- [CAI.US](https://longbridge.com/en/quote/CAI.US.md)

## Related News & Research

- [16:05 ETCaris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance](https://longbridge.com/en/news/295006825.md)
- [FluoGuide A/S Publishes Interim Report for Q2 2026](https://longbridge.com/en/news/296864861.md)
- [Regis to Issue Fourth Quarter and Full Year 2026 Results on September 1, 2026 | RGS Stock News](https://longbridge.com/en/news/296268193.md)
- [Malibu Life says total voting rights stand at 42,821,350 shares](https://longbridge.com/en/news/296743204.md)
- [Celsius Holdings to Participate in the Barclays 19th Annual Global Consumer Conference | CELH Stock News](https://longbridge.com/en/news/296617908.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**